Safety and PD-L1 expression of avelumab (MSB0010718C) in metastatic urothelial carcinoma

Description: Dr. Andrea B. Apolo, MD of the National Cancer Institute discusses Safety, clinical activity, and PD-L1 expression of avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with metastatic urothelial carcinoma from the JAVELIN Solid Tumor phase Ib trial. at ASCO GU 2016 in San Francisco.
Shared By : Genitourinary-Cancer-Meeting
Posted on : 01/09/16
Added : 4 years ago
Category : Bladder Cancer